AbbVie's Juvmo Approved by FDA for Treatment of Parkinson's Disease
The U.S. Food and Drug Administration (FDA) has approved AbbVie’s Juvmo (tavapadon) tablets as the first selective D1/D5 receptor agonist to treat adults with Parkinson’s disease. This marks a significant advancement in treatment options for patients, offering an alternative mechanism of action compared to existing therapies. The approval is based on results from AbbVie's Phase 3 TEMPO clinical program, which showed meaningful improvements in motor symptoms associated with the condition. Juvmo represents a novel approach by targeting specific dopamine receptors linked to movement control and may provide benefits for patients who do not respond well to current treatments. This regulatory milestone is expected to enhance AbbVie’s portfolio of neurological therapies and could drive growth through increased market share, particularly in Parkinson's disease treatment.
Tickers: $ABBV